| Drug Name: | Minocycline (10118-90-8) |
|---|---|
| PubChem ID: | 54675783 |
| SMILES: | CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C |
| InchiKey: | FFTVPQUHLQBXQZ-KVUCHLLUSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents |
| Molecular Weight (dalton) | : | 457.483 |
| LogP | : | 0.03 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 9 |
| Hydrogen Bond Donor Count | : | 5 |
| Total Polar Surface Area | : | 164.63 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Ethinyl Estradiol (57-63-6) | Melasma | Additive | Not understood. It seems possible that the facial pigmentation (melasma, chloasma) that can occur with oral contraceptives may have been additive with the effects of the minocycline | Minocycline-induced pigmentation occurring in two sisters |
| Perphenazine (58-39-9) | Galactorrhoea | Additive | Unknown | Black galactorrhea as a consequence of minocycline and phenothiazine therapy |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Dangerous Side Effects | Cytochrome P450 2E1 (P05181) | Theophylline inhibits CYP2E1 activity@ thus leads to reduction of minocylcine clearance and causes dangerous side effects. [ ADR Type 4 ] | Possible theophylline-minocycline interaction |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category